Serum Neurofilament-light Chain and Glial Fibrillary Acidic Proten (GFAP) Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis
Serum Neurofilament-light Chain and Glial Fibrillary Acidic Proten (GFAP) Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis
The investigators hypothesize that serum neurofilament-light chain (NfL) levels can provide information about the level of activity and progression of Multiple Sclerosis at different stages and landmarks of the disease.
In addition, Glial Fibrillary Acidic Protein (GFAP) has also been identified as another serum biomarker of disability in MS.
Inclusion Criteria:
The patient has been correctly informed.
The patient must have given their informed and signed consent.
The patient must be insured or beneficiary of a health insurance plan.
The patient is at least (≥)15 years old.
The patient has MS according to diagnosis criteria (Thompson et al. 2017) and:
Exclusion Criteria:
eric.thouvenot@chu-nimes.fr+33.(0)4.66.68.32.61
Amiens, France
AlKhedr.Abdullatif@chu-amiens.fr
eberger@chu-besancon.fr
bruno.brochet@chu-bordeaux.fr
derache-n@chu-caen.fr02 31 06 46 17
pclavelou@chu-clermontferrand.fr04 73 75 22 01
alain.creange@hmn.aphp.fr
thibault.moreau@chu-dijon.fr03 80 29 55 84
ocasez@chu-grenoble.fr04 76 76 58 71
helene.zephir@chru-lille.fr03 20 44 60 53
laurent.magy@unilim.fr05 55 05 65 61
sandra.vukusic@chu-lyon.fr04.72.35.75.22
jean.pelletier@ap-hm.fr
labauge@yahoo.fr
m.debouverie@chu-nancy.fr
lebrun.c@chu-nice.fr04 92 03 78 98
drc@chu-nimes.fr04.66.68.42.36
ogout@fo-rothschild.fr
catherine.lubetzki@psl.aphp.fr
bruno.stankoff@sat.aphp.fr
oheinzlef@chi-poissy-st-germain.fr01 39 27 41 81
jean-philippe.neau@chu-poitiers.fr05 49 44 44 46
infirmieres.recherche-clinique@chu-rennes.Fr
bertrand.bourre@chu-rouen.fr02 32 88 33 99
j.philippe.camdessanche@chu-st-etienne.fr04 77 12 78 05
jerome.de.seze@chru-strasbourg.fr03 88 12 85 44
biotti.d@chu-toulouse.fr
guennoc@univ-tours.fr02 47 47 80 23
pcabre_fr@yahoo.fr